Company
AboutTeamImpact
Science
Development ModelFocus AreasPipeline
Partnering
Business ModelPartners
Proof
Case StudiesContact
Home / Business Model

How we create value.

We front the investment and carry the development risk, then partner for value.

Business Model

Converting known molecules into differentiated, licensable assets.

SELECT

Disciplined selection

Known molecules chosen on need, feasibility and barriers.

→
DEVELOP

We fund and de-risk

In our Bangalore laboratory and through our CMO and CRO network.

→
OUTPUT

Licensable asset

A de-risked product with a complete development package.

Partners engage through three routes
LICENSING

Take the asset forward

The partner licenses the de-risked asset at the gate and leads the path to market.

Enters at the licensable gate
CO-DEVELOPMENT

Build it together

Joint workstreams and shared decisions, combining our formulation science with the partner's capabilities.

Can begin from Stage 2
CO-INVESTMENT

Share funding and risk

The partner shares the investment and the development risk, with the program jointly governed.

Can begin from Stage 2

Technology transfer follows each route, with commercial supply through our CMO network or the partner's site.

01 — SELECTION

Disciplined Product Selection

Products are chosen on unmet need, market attractiveness, regulatory feasibility, competitive barriers, and licensing potential — not novelty for its own sake.

02 — INFRASTRUCTURE

R&D Infrastructure

Development takes place at our own state-of-the-art R&D laboratory in Bangalore, India — staffed by 50+ scientists, and supplemented by academic partnerships providing on-demand access to advanced platforms including SEM, XRD, LC-MS, NGS, and high-throughput screening.

03 — PARTNERSHIP

Global Partner Network

We work with pharmaceutical companies, investors, CROs, CDMOs, and strategic partners across our UK and India operations and global markets.

04 — VALUE REALIZATION

Licensing & Technology Transfer

Development-ready products are licensed, co-developed, or transferred for commercialisation — converting technical assets into commercial value.

Capital-Light By Design

Science and regulatory risk, without plant risk.

Our model concentrates investment where value is created and keeps fixed assets out of the equation.

01 / NO FIXED ASSETS

Capital goes into the science

We develop through a network of qualified CMOs and CROs, so investment funds formulation, analytical and regulatory work rather than plant and equipment.

02 / SPEED TO START

Programs begin on established capacity

Work starts on existing partner capacity instead of waiting for facilities to be built, commissioned and validated.

03 / PORTABLE ASSETS

Designed to transfer

Processes are developed with technology transfer in mind, so a licensee can manufacture at the site or through the partner it prefers.

04 / RISK WHERE IT MATTERS

We carry the development risk

We self-fund programs through to a de-risked, licensable state, concentrating our investment on the technical and regulatory risks partners most want removed.

Next step

Discuss a program, licence or collaboration.